This Funding Opportunity Announcement (FOA) invites applications that expand on foundational research demonstrating generally improved emotional function and emotion regulation with aging, to further clarify the trajectories of change in emotion processing and linked neurobiological factors in adults who are aging normally, as well as in individuals with mild cognitive impairment (MCI), Alzheimer's disease, and related dementias (ADRD). The goal is three-fold: to advance understanding of (1) normative maturational shifts in emotional processes, (2) how dysfunction in the integrative neural-behavioral mechanisms of emotional function might manifest in MCI and the early stages of ADRD, and/or (3) how such dysfunction might account for any of the neuropsychiatric symptoms observed in ADRD. Such studies may identify novel targets for interventions or prevention efforts, or provide clues to intervention strategies that might be applied to normalize emotion dysregulation or strengthen emotional resilience at different life stages in normal aging or disease stages in MCI and ADRD.
Cooperative agreements under this funding opportunity announcement (FOA), Alzheimer's Disease Program Initiative (ADPI), are dedicated to the development and expansion of dementia-capable home and community-based service (HCBS) systems in States and Communities. There are two application options contained in this FOA, one for States (Option A) and the other for Communities (Option B). No entity would be eligible to apply for both State and Community options. The systems resulting from program activities under both program options will provide quality, person-centered services that help individuals remain independent and safe in their communities.
The Administration on Aging will hold a competition for a new cooperative agreement to continue operation of a national information and counseling service for persons with Alzheimer's disease, their family members and caregivers (National Alzheimer's Call Center). The National Call Center will be available to people in 56 states and territories, 24 hours a day, 7 days a week, 365 days a year to provide expert advice, care consultation, information and referrals at the national and local levels, regarding Alzheimer's disease and related dementias (ADRD).
This FOA invites applications from qualified institutions to create a Roybal Center Coordinating Center (CC), serving the needs of the Roybal Centers for Translational Research on Aging program as well as the Roybal Centers for Translational Research on Dementia Care Provider Support program. The Roybal Coordinating Center will serve as a hub for the Roybal Center grant program. Roybal Center programs conduct translational research in the behavioral and social sciences of aging, structured in accordance with the NIH Stage Model. Roybal Center program resources are intended for pilot and preliminary translational, multi-directional research at Stages 0 through IV of the behavioral intervention development pipeline with the goal of creating principle-driven interventions that improve the lives of mid-life and older people and the capacity of institutions to adapt to societal aging. The Roybal Coordinating Center will facilitate and coordinate trans-Roybal activities. The Center will work closely with the NIA Program Officer and, in coordination with all Roybal sites, will be responsive to requests generated by key Roybal site personnel, NIA, NIH, the scientific community, and the general public.
This FOA invites applications from qualified institutions to create a Roybal Center Coordinating Center (CC), serving the needs of the Roybal Centers for Translational Research on Aging program as well as the Roybal Centers for Translational Research on Dementia Care Provider Support program. The Roybal Coordinating Center will serve as a hub for the Roybal Center grant program. Roybal Center programs conduct translational in the behavioral and social sciences of aging, structured in accordance with the NIH Stage Model. Roybal Center program resources are intended for pilot and preliminary translational, multi-directional research at Stages 0 through IV of the behavioral intervention development pipeline with the goal of creating principle-driven interventions that improve the lives of mid-life and older people and the capacity of institutions to adapt to societal aging. The Roybal Coordinating Center will facilitate and coordinate trans-Roybal activities. The Center will work closely with the NIA Program Officer and, in coordination with all Roybal sites, will be responsive to requests generated by key Roybal site personnel, NIA, NIH, the scientific community, and the general public.
The National Institute on Aging (NIA) invites applications specific to infrastructure that will support, under a single cooperative agreement (U24), phenotypic data harmonization on subjects with Alzheimer's Disease Sequencing Project (ADSP) genetic and genomic data. These data will become a long-lived legacy data set that will be perpetually curated. The FOA will fund a single vanguard network of researchers with expertise in genetics, epidemiology, and clinical specialties who will work with the ADSP and with study cohort leads on data harmonization efforts to optimize the ability to identify well- targeted therapeutic approaches for Alzheimer's disease and related dementias (AD/ADRD).
This FOA invites applications for a National Alzheimer's Coordinating Center (NACC) whose purpose is to serve NIA and the Alzheimer's disease (AD) and Alzheimer's disease- related dementias (AD/ADRD) field as 1) a national data resource, collecting data from the Alzheimer's Disease Research Centers (ADRCs), affiliated data, and sample repositories; 2) a facilitator of current and future AD/ADRD research; and 3) the central hub for organizing and enabling communication within and outside the ADRC program, including annual meetings and steering committees.
Cooperative agreements under this funding opportunity announcement (FOA), Alzheimer's Disease Program Initiative (ADPI), are dedicated to the development and expansion of dementia-capable home and community-based service (HCBS) systems in States and Communities. There are two application options contained in this FOA, one for States (Option A) and the other for Communities (Option B). No entity would be eligible to apply for both State and Community options. The systems resulting from program activities under both program options will provide quality, person-centered services that help individuals remain independent and safe in their communities.
This Funding Opportunity Announcement (FOA) supports concerted efforts that take a multipronged, team science strategy and apply high throughput, genome-wide approaches to systematically discover and characterize functional genomic and epigenomic elements; and elucidate and validate their functional roles and mechanisms of action underpinning the heterogeneity, pathogenesis, and progression of Alzheimers disease andrelated dementias (AD/ADRD).
This Funding Opportunity Announcement (FOA) supports concerted efforts that take a multipronged, team-science strategy and apply high-throughput, genome-wide approaches to systematically discover and characterize functional genomic and epigenomic elements and elucidate and validate their functional roles and mechanisms of action underpinning the heterogeneity, pathogenesis, and progression of Alzheimer's disease and related dementias (AD/ADRD).
REM sleep behavior disorder (RBD) is a parasomnia that presents with abnormal dream mentation, abnormal behaviors, and increased electromyographic tone on polysomnography during REM sleep. Older individuals with RBD frequently develop neurodegenerative diseases, particularly α-synucleinopathies: Parkinson's disease (PD), Lewy Body Dementia (LBD), and Multi-System Atrophy (MSA). Individuals with idiopathic RBD (iRBD) develop an overt synucleinopathy at high rates: 40-50% in 5 years and 80-92% in long-term follow up. iRBD provides a unique opportunity to understand the clinical development and evolution of α-synucleinopathies, as well as a potential path for developing disease prevention therapies. While it is not possible at this time to identify whether a person will develop PD, LBD, or MSA, iRBD is a preclinical/prodromal phase of neurodegenerative, particularly α-synucleinopathy, illness. The current iRBD research community includes investigators and centers across North America and the world. There have been attempts to carry out multi-center iRBD research, but interpretation of findings has been complicated by small numbers of iRBD subjects at individual centers; differences in assessment protocols, including collection methods for cognitive and biomarker data; and variability in diagnostic procedures at different centers. This FOA seeks to develop and support a consortium of investigators who will establish a common iRBD research protocol to collect and share harmonized clinical, cognitive, and biomarker data, establishing a centralized repository of biosamples from individuals with iRBD as they progress from prodromal α-synucleinopathy to PD, LBD, or MSA.
Studies have found that older adults who participate in what they see as meaningful activities, like volunteering in their community, reported feeling healthier and happier. Other studies have found that older adults who have a full social network and participate in many social activities tend to have less cognitive decline and a decreased risk of dementia than those who are not socially engaged do. The Administration on Aging is interested in increasing ACL and the Aging Network’s understanding of what constitutes good practice for promoting and supporting social engagement among older adult and expanding the reach of the Aging Network to more effectively serve older adults by providing tools and resources necessary for aging organizations to assist older adults to remain socially engaged and active.
This FOA encourages preclinical and clinical research to study whether, and how, different neurodegenerative disease processes interact with one another to initiate and/or hasten progression of neuropathology and dementia.
The goal of this funding opportunity announcement is to continue and expand the open-science, systems-biology enterprise of the AMP-AD Target Discovery and Preclinical Validation Consortium and enable data-driven discovery and validation of novel targets and biomarkers for AD and AD-related dementias through the development of predictive network models of brain health and disease.
The goal of this funding opportunity announcement is to solicit applications focused on 1) providing data enablement for the open-science, systems-biology enterprise of the AMP-AD Target Discovery and Preclinical Validation Consortium supported through the companion FOA (RFA-AG-18-013) and 2) sustaining and expanding the big-data infrastructure of the AMP-AD Knowledge Portal as a collaborative research platform through which members of the Consortium, researchers at large, and citizen scientists can engage in rapid translational learning and contribute to the development of predictive models of AD and AD-related dementias.
The purpose of this funding opportunity announcement (FOA) is to provide infrastructure support to advance development of operational definitions and approaches for the study of the concepts of cognitive reserve and resilience to Alzheimer's disease and related dementias (ADRD) and age-related cognitive decline. The infrastructure support will facilitate a collaborative research network through meetings, conferences, small-scale pilots, and dissemination activities to foster development and champion use of state-of-the-art definitions, uniform nomenclature, and validated approaches that will be key to the advancement of research on maintenance of brain and cognitive health and treatment and/or prevention of ADRD.
The goal of this funding opportunity announcement is to continue and expand the open-science, systems-biology enterprise of the AMP-AD Target Discovery and Preclinical Validation Consortium and enable data-driven discovery and validation of novel targets and biomarkers for AD and AD-related dementias through the development of predictive network models of brain health and disease.
The goal of this funding opportunity announcement is to solicit applications focused on 1) providing data enablement for the open-science, systems-biology enterprise of the AMP-AD Target Discovery and Preclinical Validation Consortium supported through the companion FOA (RFA-AG-18-013) and 2) sustaining and expanding the big-data infrastructure of the AMP-AD Knowledge Portal as a collaborative research platform through which members of the Consortium, researchers at large, and citizen scientists can engage in rapid translational learning and contribute to the development of predictive models of AD and AD-related dementias.
Alzheimer's disease (AD) is a progressive, degenerative disorder of the brain and is the most common form of dementia of the elderly. AD is the sixth leading cause of death in the United States. Prominent behavioral manifestations of AD include memory impairments and decline in other cognitive domains. Currently, at least five million Americans at age 65 and older suffer from AD, and it is projected that the number of new cases of AD will double by 2025. AD is clearly becoming a national health crisis affecting Americans across the country, and the total annual payments of health care for people with AD are projected to be more than $1 trillion in 2050. In response to this looming public health crisis, the National Alzheimer's Project Act (NAPA) was signed into law in 2011. The primary research goal of the NAPA is to prevent the onset of, and develop effective treatments for, AD by 2025. As part of the strategic planning process to implement NAPA, NIH AD Research Summits were held in 2012 and 2015 and identified research priorities and strategies needed to accelerate basic research and the development of effective therapies. A FY2017 Alzheimer's disease bypass budget with milestones was published in 2015 to establish research and funding priorities in response to the NAPA and the AD Research Summits (https://www.nia.nih.gov/alzheimers/bypass-budget-fy2017). This funding opportunity announcement was developed in response to the recommendations of the AD Research Summits and milestones published in the FY2017 Alzheimer's disease bypass budget to support interdisciplinary research to understand the heterogeneity and multifactorial etiology of AD.
Alzheimer's disease (AD) is a progressive, degenerative disorder of the brain and is the most common form of dementia of the elderly. AD is the sixth leading cause of death in the United States. Prominent behavioral manifestations of AD include memory impairments and decline in other cognitive domains. Currently, at least five million Americans at age 65 and older suffer from AD, and it is projected that the number of new cases of AD will double by 2025. AD is clearly becoming a national health crisis affecting Americans across all regions of the country, and the total annual payments of health care for people with AD are projected to be more than $1 trillion in 2050. In response to this looming public health crisis, the National Alzheimer's Project Act (NAPA) was signed into law in 2011. The primary research goal of the NAPA is to prevent the onset of and develop effective treatments for AD by 2025. As part of the strategic planning process to implement NAPA, NIH AD Research Summits were held in 2012 and 2015 and identified research priorities and strategies needed to accelerate basic research and the development of effective therapies. A FY2017 Alzheimer's disease bypass budget with milestones was published in 2015 to establish research and funding priorities in response to the NAPA and the AD Research Summits (https://www.nia.nih.gov/alzheimers/bypass-budget-FY 2017). This funding opportunity announcement was developed in response to the recommendations of the AD Research Summits to support interdisciplinary research to understand the heterogeneity and multifactorial etiology of AD.
